- Home
- NITO vs HSDT Comparison
NITO vs HSDT Comparison
Compare NITO & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NITO
- HSDT
- Stock Information
- Founded
- NITO 2009
- HSDT 2014
- Country
- NITO Israel
- HSDT United States
- Employees
- NITO N/A
- HSDT N/A
- Industry
- NITO
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NITO
- HSDT Health Care
- Exchange
- NITO NYSE
- HSDT Nasdaq
- Market Cap
- NITO 1.9M
- HSDT 1.8M
- IPO Year
- NITO N/A
- HSDT N/A
- Fundamental
- Price
- NITO $0.21
- HSDT $0.45
- Analyst Decision
- NITO
- HSDT Buy
- Analyst Count
- NITO 0
- HSDT 2
- Target Price
- NITO N/A
- HSDT $24.00
- AVG Volume (30 Days)
- NITO 882.1K
- HSDT 98.6K
- Earning Date
- NITO 11-14-2024
- HSDT 11-12-2024
- Dividend Yield
- NITO N/A
- HSDT N/A
- EPS Growth
- NITO N/A
- HSDT N/A
- EPS
- NITO N/A
- HSDT N/A
- Revenue
- NITO $175,308.00
- HSDT $502,000.00
- Revenue This Year
- NITO N/A
- HSDT $16.41
- Revenue Next Year
- NITO N/A
- HSDT $31.97
- P/E Ratio
- NITO N/A
- HSDT N/A
- Revenue Growth
- NITO N/A
- HSDT N/A
- 52 Week Low
- NITO $0.17
- HSDT $0.37
- 52 Week High
- NITO $7.55
- HSDT $9.50
- Technical
- Relative Strength Index (RSI)
- NITO 43.67
- HSDT 39.67
- Support Level
- NITO $0.19
- HSDT $0.42
- Resistance Level
- NITO $0.23
- HSDT $0.49
- Average True Range (ATR)
- NITO 0.02
- HSDT 0.06
- MACD
- NITO -0.00
- HSDT -0.01
- Stochastic Oscillator
- NITO 50.00
- HSDT 16.98
About NITO N2OFF INC
N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork.
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.